Sangart has entered into this CRADA with the US Naval Medical Research Center and the Uniformed Services University of Health Sciences.
The agreement will allow the US Navy to evaluate the oxygen carrying capacity and effectiveness of MP4 in traumatic brain injury.
Sangart president and CEO Brian O’Callaghan said that they look forward to working with the US Navy to evaluate MP4 in this important potential application.
"If these studies result in positive findings for MP4, it could potentially lead to better treatment options for the many service people and civilians that are victims of traumatic brain injury," O’Callaghan said.